2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 322-334. PMID: 35390768, DOI: 10.6004/jnccn.2022.0021.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaNCCN guidelinesClassical HLNodular lymphocyte predominant Hodgkin lymphomaLymphocyte predominant Hodgkin lymphomaNCCN Guidelines InsightsModern treatment optionsManagement of patientsB-cell originClassical Hodgkin lymphomaLong-term toxicityUncommon malignancyCure rateTreatment optionsTreatment considerationsDose constraintsLymphomaRecent updatesGuidelinesPatientsMalignancy
2019
Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center
Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.Peer-Reviewed Original ResearchSmilow Cancer HospitalMultiple myelomaRefractory MMInfusion reactionsSpeakers bureauCancer HospitalReal-word experienceReal-world practice patternsAnti-plasma cell therapyTransplant-eligible patientsYale Cancer CenterInfusion-related reactionsAdverse event profileLeukotriene receptor antagonistsProgression-free survivalRefractory multiple myelomaPatient-reported qualityManagement of patientsOverall response rateJanssen Scientific AffairsClonal plasma cellsExcellent safety profileMulti-center studyDrug combination regimensInfusion reaction rates